Improving Outcomes for Patients With Moderate to Severe Psoriasis
Source: Improving Outcomes for Patients With Moderate to Severe Psoriasis

Interactive Virtual Presentation

In this CME-certified interactive presentation, M. Alan Menter, MD, discusses strategies to optimize disease response, symptom improvement, and comorbidity management for patients with moderate to severe psoriasis based on recent guidelines and available clinical data.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate patient-reported outcomes and validated assessment tools into the assessment and management of patients with psoriasis in order to optimize clinical response and symptom improvement
  • Routinely incorporate cardiovascular risk assessment and management into the care of patients with psoriasis
  • Assess new and emerging clinical efficacy and safety data for currently available and novel agents in order to formulate appropriate treatment plans for patients with moderate to severe psoriasis

Topics Covered Include:

  • Overview
  • Expert Insights
  • Long-term Safety of Biologics
  • Key Comorbidities: Managing Cardiovascular Risk
  • Key Comorbidities: Managing Depression
  • Patient-Reported Outcomes and Assessment of Severity
  • Summary
CCO Interactive Virtual Presentations contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Faculty

  • M Alan Menter
    MD

Credit Information

  • Release Date:
    October 14, 2016
  • Expiration Date:
    October 13, 2017
  • Physicians:
    maximum of 0.75 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

M Alan Menter, MD


Chairman of Dermatology
Baylor University Medical Center at Dallas
Dallas, Texas

M. Alan Menter, MD, has disclosed that he has received funds for research support from AbbVie, Allergan, Amgen, Anacor, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, LEO Pharma, Merck, Neothetics, Novartis, Pfizer, Regeneron, Symbio/Maruho, and XenoPort; has received consulting fees from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Vitae, and XenoPort; and has received fees for non-CME/CE services from AbbVie, Amgen, Janssen, and LEO Pharma.
 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has nothing to disclose with regard to commercial interests.
 

Megan K. Murphy, PhD


Clinical Editor

Megan Murphy, PhD, has nothing to disclose with regard to commercial interests.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has nothing to disclose with regard to commercial interests.
 

CME Course Director
Allison Larson, MD, Assistant Dean of Academic Affairs, Assistant Professor of Dermatology, Boston University School of Medicine, has nothing to disclose with regard to commercial interests.

Program Manager
Elizabeth Drury, Boston School of Medicine, has nothing to disclose with regard to commercial interests.

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

 

Target Audience

This activity is intended for dermatologists, internists, family physicians, nurse practitioners, physician assistants, pharmacists, and other healthcare providers involved in the care of patients with moderate to severe psoriasis.


Goal

The goal of this activity is to improve the knowledge and competence of clinicians who provide care for patients with moderate to severe psoriasis.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate patient-reported outcomes and validated assessment tools into the assessment and management of patients with psoriasis in order to optimize clinical response and symptom improvement
  • Routinely incorporate cardiovascular risk assessment and management into the care of patients with psoriasis
  • Assess new and emerging clinical efficacy and safety data for currently available and novel agents in order to formulate appropriate treatment plans for patients with moderate to severe psoriasis
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Clinical Care Options, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Lilly USA, LLC., and Novartis Pharmaceuticals Corporation.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 14, 2016, through October 13, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.